The PCR assay in the preclinical safety evaluation of nucleic acid medicines

Human and Experimental Toxicology

Volumn 19, Issue 5, 2000, Pages 267-276

  Haworth, R ^a   Pilling, A M ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Molecular Pathology Group   (United Kingdom)

Author keywords

Integration; Nucleic acid medicines; Polymerase chain reaction

Indexed keywords

DNA; DNA ANTIBODY; DNA VACCINE; GENE PRODUCT; MESSENGER RNA; NUCLEIC ACID;

ARTICLE; ASSAY; AUTOIMMUNITY; CONTAMINATION; DNA INTEGRATION; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GOOD LABORATORY PRACTICE; HISTOLOGY; MULTIPLE CHEMICAL SENSITIVITY; MUTAGENESIS; NONHUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAFETY; SAMPLING; TECHNIQUE; TOXICITY; TOXICOLOGY;

EID: 0033853136     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700678815891     Document Type: Article

References (4)

1. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-1354.
2. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symposia on Quantitative Biology 1986; 51 Pt 1: 263-273.
3. Saiki RK, Gelfand DH, Stoffel S, et al Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491.
4. Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science 1991; 252: 1643-1651.